Association between naproxen use and protection against acute myocardial infarction

Archives of Internal Medicine

Volumn 162, Issue 10, 2002, Pages 1111-1115

  Rahme, Elham ^a,b   Pilote, Louise ^a,b   LeLorier, Jacques ^c  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; MECLOFENAMATE SODIUM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ACUTE HEART INFARCTION; ADULT; AGED; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROTECTION; DRUG EFFECT; FEMALE; HEART PROTECTION; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

EID: 0037182023     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.10.1111     Document Type: Article

References (31)

1. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs
2. ARAMIS toxicity measurement (Arthritis Rheumatism and Aging Medical Information System)
3. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy
4. NSAID gastropathy
5. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: The second hundred years
6. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers
7. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
8. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis
9. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium
10. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial
11. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
12. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
13. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
14. Comparison of the effects of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen and placebo on gastroduodenal mucosa of patients with osteoarthritis
15. Risk of cardiovascular events associated with selective COX-2 inhibitors
16. NSAIDS. Selective COX-2 inhibitors: Competition between gastroprotection and cardioprotection
17. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: Retrospective cohort study of an elderly population
18. Changes in the treatment and outcomes of acute myocardial infarction in Quebec, 1988-1995
19. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma
20. Risk of ocular hypertension or openangle glaucoma in elderly patients on oral glucocorticoids
21. A chronic disease score from automated pharmacy data
22. Patterns of interchange in the dispensing of non-steroidal anti-inflammatory drugs
23. Cyclooxygenase-2: A major therapeutic advance?
24. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
25. Stabilization of cardiac lysosomal and cellular membranes in protection of ischemic myocardium due to coronary occlusion: Efficacy of the nonsteroidal anti-inflammatory agent, naproxen
26. Differential effects of aspirin and nonaspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women
27. Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis
28. Anticoagulants in acute coronary syndromes
29. Aspirin: New cardiovascular uses for an old drug